Background and Aim: Hepatitis B virus (HBV) load and antigens are related to the innate and adaptive immunity of chronic hepatitis B (CHB) patients. As a new HBV biomarker, the role of pregenomic RNA (pgRNA) in host immunity is not known. This study aimed to identify the relationship between serum HBV pgRNA and host immunity in CHB patients.
| INTRODUCTION
Chronic hepatitis B virus (HBV) infection still affects more than 240 million people worldwide and induces the development of liver cirrhosis, liver failure, and hepatocellular carcinoma. 1 HBV is noncytopathic to hepatocytes, and HBV-related liver damage is caused by chronic immune inflammation. During the course of liver disease, adaptive immunity is crucial for the pathogenesis of hepatic inflammation, especially T cells, which play important roles in the antiviral response. [2] [3] [4] T-cell activity largely depends on the differentiation of naïve T cells into effector T cells or T-helper cell subsets by releasing cytokines. 5 In addition to T cells, studies on chronic hepatitis B (CHB) patients in different disease phases identified a genetic signature of rigorous B-cell activation in patients in the chronic active phase. 6 In HBV infection, the importance of B cells is limited to not only their ability to produce neutralizing antibodies but also to act as potent antigen-presenting cells, particularly for helper T cells, 7 and have been shown to play a regulatory role in that context. Interleukin-10 (IL-10)-producing B cells are enriched in CHB patients, particularly during hepatic flares, and have been shown to modulate not only inflammatory events but also HBV-specific T-cell responses. 8 HBV virus DNA load and antigens, such as HBsAg and HBeAg, are thought to be related to the innate and adaptive immunity of CHB patients. For example, as the HBV DNA load increases, the activation and function of immune cells are suppressed. Sustained exposure to high quantities of viral antigens is thought to contribute to defects in T-cell function by interacting with and modulating T cells directly or through the induction of immunosuppressive cytokines and the inflammatory liver environment. [9] [10] [11] [12] Intrahepatic covalently closed circular DNA (cccDNA) is the transcription template of all HBV transcripts, and HBV produces messenger RNAs (mRNAs), 2.4 and 2.1 kb surface mRNAs and 0.7 kb X mRNA, and the 3.5 kb pregenomic RNA (pgRNA) intracellularly. [13] [14] [15] [16] Gene sequences of HBV RNA were found to be comparable in serum and liver tissue, indicating that serum HBV RNA originates from the infected hepatocytes. 17 However, the mechanism underlying the release of HBV RNA into serum from infected hepatocytes remains unclear. 18 The available study results suggested that serum HBV RNA species might vary depending on the detection method, CHB stage or antiviral treatment. 17, [19] [20] [21] [22] [23] [24] [25] [26] However, serum HBV RNA is probably a mixture of intact, spliced, and polyA-free pgRNA, and the detected serum HBV RNA sequences are predominantly derived from pgRNA. 18 Transcription from cccDNA to pgRNA is an important step in HBV replication, and pgRNA is regarded as the template for the reverse transcription and synthesis of the HBV genome. [27] [28] [29] Serum HBV pgRNA can be detected in the sera of CHB patients, [20] [21] [22] although its levels are significantly lower than HBV DNA levels. 27 Serum HBV pgRNA is regarded as an important biomarker that could reflect the persistence of HBV infection, HBV replication and rebound, 19, 30 intrahepatic cccDNA transcriptional activity in the liver tissues of CHB patients, 30, 31 and is also regarded as an early predictor of antiviral therapy, [20] [21] [22] 26 emergence of HBV drug resistance, or safe withdrawal of nucleoside analog (NUC) therapy. 32 Since serum HBV pgRNA has recently been regarded as an important new biomarker reflecting HBV replication and HBVrelated immune-mediated inflammatory liver injury is induced by components of the virus, it is important to determine whether serum HBV pgRNA also has a relationship with host immunity, similar to HBsAg or HBV DNA, in CHB patients. However, little is known about this relationship. In this study, HBV antigens and antibodies, serum cytokine profiles, Th1/Th2 cells, and serum HBV pgRNA were examined in a relatively large cohort of treatment-naïve CHB patients to identify the relationship between serum HBV pgRNA and host immunity.
| SUBJECTS AND METHODS

| Patients
Two hundred twenty-five treatment-naïve CHB were recruited from the hepatitis clinic at the Third Affiliated Hospital of Sun Yat-sen University. Patients who were previously receiving antiviral treatment (interferon or nucleoside analogs), were coinfected with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus, had an autoimmune disease or fatty liver disease, were receiving immunosuppressive therapy, or had cirrhosis or malignancies were excluded.
Written informed consent was obtained from all patients before their inclusion in the study. The study conforms to the Declaration of Helsinki and was approved by the Institute Review Board of Sun Yat-sen University. Demographic and laboratory information is listed in Table 1 . Healthy controls were simultaneously recruited from The Physical Examination Center.
| Clinical and serological parameters
HBsAg, anti-HBsAg, HBeAg, and HBeAb were tested using commercial kits (Abbott Laboratory, North Chicago, IL). qHBsAg was measured using Elecsys HBsAg II Quant reagent kits (Roche Diagnostics, Indianapolis, IN).
HBcAb levels were semiquantified with a chemiluminescence immunoassay (Roche Diagnostics). Serum HBV DNA levels were measured by Roche COBAS AmpliPrep/COBAS TaqMan HBV Test v2.0 (range from 20 to 1.7E+08 IU/mL; Roche Molecular Diagnostics, Branchburg, NJ).
HBV genotypes and C/PreC/basal core promoter (BCP) mutations were determined by direct sequencing. Healthy controls had no history of liver or other diseases, did not have HBV infection, and had normal liver functions.
| Quantification of serum HBV pgRNA
Serum HBV pgRNA levels were tested as described by Wang et al 19 and van Campenhout et al 33 
| Th1/Th2 cells
Peripheral blood monouclear cells (PBMCs) were stimulated with
Leukocyte Activation Cocktail (eBioscience) at 37°C for 4 hours before intracellular staining using the PharMingen staining protocol.
The cells were stained with PE-CF594-CD3, APC-CD4, and 
| Statistical analysis
The average levels of serum HBV pgRNA are described as median values (quartile spacing) and expressed in the logarithm10 form.
Samples with undetectable serum HBV pgRNA were assigned a value of 0 log 10 copies/mL for the data analysis. Nonparametric test analyses were used. We compared patient groups using the Mann- among the patient groups and were higher in group II than in the other three groups (P = .041). The serum HBV PgRNA levels of group I were significantly higher than those of groups III and IV (P < .001). However, the serum HBV pgRNA levels in groups III and IV were comparable (P = .316) ( Figure S1A ).
The distribution of serum HBV pgRNA levels was also examined among the immune tolerant (IT), immune active (IA), inactive carriers (IC), and gray zone (GZ) phases categorized according to the American Association for the Study of Liver Disease guidelines. 1 The average serum HBV pgRNA levels of patients at the four phases were 6.05 (5.72, 6.36), 5.93 (2.41, 6.89), 0.00 (0.00, 1.81) and 1.24 (0.00, 3.13) log 10 copies/mL, respectively. The average levels of serum HBV pgRNA in patients in both IT and IA groups were higher than those in GZ and IC groups (P < .001). However, there were no statistically significant differences in serum HBV pgRNA levels between IT and IA groups (P > .05) or between GZ and IC groups (P > .05) ( Figure S1B ). However, no significant correlation was observed between serum HBV pgRNA and HBsAg levels (P = .07) in HBeAg(−) patients ( Figure   1A ). We further studied the relationship of serum HBV pgRNA levels [0.00, 2.80] log 10 copies/mL; P < .001) ( Figure 1D ). We then compared 
| Association with HBV antigens and antibodies
| Association with HBV DNA load
The association between serum levels of HBV pgRNA and HBV DNA was analyzed in a total of 225 subjects. The average serum HBV pgRNA level was 3.13 (0.00, 6.16) log 1 copies/mL, lower than that of Figure 2C ).
As mentioned above, serum HBV pgRNA levels were significantly higher in HBeAg(+) patients than in HBeAg(−) patients ( Figure 1D) .
Similarly, the serum HBV DNA levels in HBeAg(+) patients were higher than those in HBeAg(−) patients (6.19 [5.40, 7 .66] vs 1.17
[0.00, 4.78] log 10 IU/mL; P < .001) ( Figure 2D ). Therefore, compared with HBeAg(−) patients, HBeAg(+) patients had higher levels of both HBV DNA and serum HBV pgRNA, suggesting that the distribution of serum HBV pgRNA levels was similar to that of HBV DNA. Figure 3F ). Because the HBV DNA levels were not comparable in HBeAg(−) patients with normal and elevated ALT levels (P = .006), the above analysis was not performed in these patients. Monitoring the intrahepatic cccDNA level is clinically significant for evaluating the antiviral therapy efficacy and predicting the therapy endpoint, which currently relies on liver biopsy. Several obstacles prevent the widespread use of liver biopsies, such as liver invasion, potential complications, and inadequate specimen size. 36, 37 Because serum HBV pgRNA was thought to be a biomarker for the persistence of active intrahepatic cccDNA, we explored the relationship between serum HBV pgRNA and HBV DNA in this study. Similar to intrahepatic cccDNA, 30, 31, 35 a positive correlation was also found between serum HBV pgRNA and HBV DNA by both correlation and linear regression analyses, indicating that serum HBV pgRNA might be a suitable marker for persistent HBV infection.
| Association with liver inflammation
| Regression analysis of virological and clinical factors associated with serum HBV PgRNA levels
Early studies indicated that serum pgRNA was found in exosomes. 38, 39 Chou et al 40 histopathological scores, and one of their mechanistic explanations was that HBV RNA produced in hepatocytes could be released into circulation in proportion to the intensity of liver cell necroinflammation. In a study by van Campenhout et al, 33 HBV RNA levels were significantly higher in patients with higher ALT levels than in those with lower ALT levels. In our results, serum HBV pgRNA levels were also positively correlated with ALT in patients with comparable HBV DNA levels, supporting other researchers' opinions that serum HBV pgRNA particles could be released from injured hepatocytes. 17 Furthermore, we found that serum HBV pgRNA was associated with Th1/Th2 immunity, which plays an important role in liver inflammation, potentially contributing to the association of serum HBV pgRNA with ALT.
HBV DNA fragments can integrate into the human genome and produce serum HBsAg, suggesting that serum HBsAg is not an optimal viral marker of intrahepatic cccDNA replication activity in CHB patients. [41] [42] [43] [44] [45] [46] Serum HBV pgRNA is a new and important marker for intrahepatic HBV replication that could predict early NUC efficacy and prognosis of CHB patients and be used to monitor HBV resistance during NUC therapy. [19] [20] [21] 26, 32, 35 Indeed, we herein found that serum HBV pgRNA was significantly correlated with most of the commonly used HBV replication markers, such as HBV DNA, HBsAg, and HBeAg status, which supports that serum HBV pgRNA might be an optional marker to reflect intrahepatic HBV replication activity.
However, one should rule out the effect of ALT and HBV mutations when assessing HBV replication with this potential indicator because both of these mutations were also well correlated with serum HBV pgRNA. Abbreviations: CI, confidence interval; IFN-γ, interferon-γ; IL, interleukin; pgRNA, pregenomic RNA; TNF-α, tumor necrosis factor-α. 
